Results 91 to 100 of about 51,276 (310)

Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE [PDF]

open access: yes, 2015
Introduction: The current mainstay of the treatment of thrombotic antiphospholipid syndrome (APS) is long-term anticoagulation with vitamin K antagonists (VKAs) such as warfarin. Non-VKA oral anticoagulants (NOACs), which include rivaroxaban, have been
Clawson, S   +7 more
core   +1 more source

Intravesicular Onabotulinumtoxin A Hemorrhage on Rivaroxaban

open access: yesCase Reports in Obstetrics and Gynecology, 2019
Overactive bladder (OAB) is urgency, with or without urgency incontinence. For OAB, an injection of onabotulinumtoxin A (BOTOX®) can be a low-risk outpatient procedure. We present a patient on a novel anticoagulant that experienced excessive bleeding after this procedure.
Allison Eubanks   +2 more
openaire   +4 more sources

Restarting Oral Anticoagulation in Patients With Atrial Fibrillation After Admission for a Gastrointestinal Bleeding Event: Effectiveness and Safety of Direct Oral Anticoagulants Compared to Warfarin

open access: yesPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, EarlyView.
ABSTRACT Background There are sparse data to guide resumption of direct oral anticoagulants (DOACs) versus warfarin in patients with atrial fibrillation (AF) who survive a major gastrointestinal bleeding (GIB) event. Objective To compare the risk–benefit profile of restarting DOACs versus warfarin among patients with AF following hospitalization for ...
Oluwadolapo D. Lawal   +8 more
wiley   +1 more source

Portal Venous Thrombosis Associated with Use of Etonogestrel/ethinyl Estradiol Vaginal Ring [PDF]

open access: yes, 2020
Introduction: Portal venous thrombosis is a life-threatening cause of abdominal pain. In younger patients, heritable thrombophilias, pregnancy, tobacco use, and oral contraceptives are associated.Case Report: A 26-year-old woman prescribed contraceptive ...
Bailey, Katelynn E.   +1 more
core  

Coagulation and anticoagulation in idiopathic pulmonary fibrosis [PDF]

open access: yes, 2015
Idiopathic pulmonary fibrosis (IPF) is an incurable, progressive interstitial lung disease with a prognosis that is worse than that of many cancers. Epidemiological studies have demonstrated a link between IPF and thrombotic vascular events.
Crooks, Michael G., Hart, Simon P.
core   +3 more sources

A Multicenter, Open‐Label Study to Assess the Safety of Nebulized Tissue Plasminogen Activator for the Acute Treatment of Pediatric Plastic Bronchitis: The PLATyPuS Trial

open access: yesPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, EarlyView.
ABSTRACT Introduction Pediatric plastic bronchitis (PB) is a rare complication of surgically palliated congenital heart disease (CHD). Fibrin casts obstruct airways and can cause respiratory distress. There are no therapeutics approved by the United States Food and Drug Administration to treat PB, but inhaled tissue plasminogen activator (tPA) has been
Kathleen A. Stringer   +10 more
wiley   +1 more source

NOACs versus warfarin for stroke prevention in patients with AF : a systematic review and meta-analysis [PDF]

open access: yes, 2016
Acknowledgments Revman software was used for meta-analysis, a free download from the Cochrane Collaboration. GRADE pro software was used to formulate the GRADE summary of findings table, a free download from the GRADE working group.Peer reviewedPublisher
Eisinga, Anne   +2 more
core   +1 more source

Development of a physiologically‐based pharmacokinetic model for Ritonavir characterizing exposure and drug interaction potential at both acute and steady‐state conditions

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 523-539, March 2025.
Abstract Ritonavir (RTV) is a potent CYP3A inhibitor that is widely used as a pharmacokinetic (PK) enhancer to increase exposure to select protease inhibitors. However, as a strong and complex perpetrator of CYP3A interactions, RTV can also enhance the exposure of other co‐administered CYP3A substrates, potentially causing toxicity.
Lien Thi Ngo   +5 more
wiley   +1 more source

High INR on warfarin [PDF]

open access: yes, 2015
The bottom line Clarify the warfarin dose that the patient is taking, and check for co-existing problems (such as liver disease or cancer), dietary changes, and intake of alcohol and other drugs that may increase risk of bleeding or affect ...
Chevassut, Timothy J   +2 more
core   +1 more source

Rivaroxaban-Induced Hypersensitivity Syndrome

open access: yesThe Canadian Journal of Hospital Pharmacy, 2017
-
Arnaud Canneva   +3 more
openaire   +3 more sources

Home - About - Disclaimer - Privacy